This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Recently Published Economic Analysis Highlights The Financial Impact Of Attention-Deficit/Hyperactivity Disorder (ADHD) In The United States (US)

PHILADELPHIA, October 26, 2012 /PRNewswire/ --

A recently published systematic literature review and analysis of applicable studies has assessed the economic impact of ADHD in the United States. This analysis estimated that annual national excess costs for ADHD ranged from $143 billion to $266 billion. More than 70 percent of these overall excess costs were attributable to adults with ADHD or to adult family members of patients with ADHD. The analysis was published in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP).

This analysis was designed and conducted by health economists from Tufts Medical Center, the University of Pennsylvania and the Global Health Economics & Outcomes Research group at Shire Specialty Pharmaceuticals. To date, this is the most comprehensive analysis of published data relating to incremental - or excess - costs of ADHD across age groups, including children, adolescents and adults. Incremental costs included those associated with overall healthcare, productivity and income losses, and the educational and judicial systems.  

For individuals with ADHD, the excess costs for each category were estimated by comparing the relevant costs against those of individuals who were not diagnosed with ADHD. For family members of individuals with ADHD, costs were compared to those of individuals who did not have a family member with ADHD. The excess costs were then extrapolated to the entire US population using established scientific methodologies.

The analysis estimated that the national excess costs for adults with ADHD or adult family members of patients with ADHD were almost three times higher than for children and adolescents with ADHD. Workplace productivity and income losses were the largest contributors to the economic burden associated with adults with ADHD, ranging from $87 billion to $138 billion and accounting for more than 70 percent to 80 percent of the overall costs in adults.

In children and adolescents with ADHD, the economic burden was also substantial, ranging from $38 billion to $72 billion. The largest cost categories were healthcare costs, ranging from $21 billion to $44 billion annually, and education costs, ranging from $15 billion to $25 billion annually.

The analysis did not evaluate the impact of treatment interventions on excess costs due to the lack of available data. In addition, insufficient studies were available to assess the economic burden of traffic accidents and substance abuse in this population.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs